Takeda Pharmaceutical Co Ltd
Rusfertide
Polycythemia Vera
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews Rusfertide for Polycythemia Vera around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 6-K
verified 13h ago
“Rusfertide has received Breakthrough Therapy designation, Orphan Drug designation and Fast Track designation from the U.S. FDA.”